Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

Dexcom, Inc., a leading company in glucose biosensing, has announced a strategic collaboration with ŌURA, the manufacturer of a prominent smart ring, to enhance metabolic health management.

A new deal with diabetes specialists Dexcom will let diabetes patients see continuous glucose monitor (CGM) data on Fitbit’s new Ionic smartwatch. Part of a broader initiative between the two ...

Shares of DexCom Inc. DXCM slid 1.37% to $87.53 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.65% to ...

Furthermore, you'd generally like to see... Investing.com -- Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts.

Shares of DexCom Inc. DXCM slid 2.58% to $78.92 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.19% to 6,075.11 and ...